Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies.
Twenty patients with alopecia universalis, alopecia semiuniversalis and alopecia areata were studied for their immune parameters. Fourteen of them received an oral treatment with Isoprinosine, a synthetic immunomodulator. Ten patients showed the presence of several autoantibodies. No significant abnormalities in various T cell rosette markers were found, but T4/T8 ratios tended to be elevated. Erythrocyte antibody complement (EAC) rosettes were usually decreased. Treatment with Isoprinosine produced a clinical response, as judged by total or partial hair growth, in nine of the fourteen patients treated. It was striking to observe that seven of the nine responders had autoantibodies prior to treatment. These autoantibodies disappeared or decreased with Isoprinosine therapy. In contrast, only one of five nonresponders had serum autoantibodies. After treatment, both groups showed an increase in blood-active T rosettes. These results suggest that alopecia is a heterogeneous disease subdivided by the presence or absence of autoantibodies since clinical response was mainly obtained in patients presenting autoantibodies.
Lowy
M
M
Ledoux-Corbusier
M
M
Achten
G
G
Wybran
J
J
D000293:Adolescent; D000328:Adult; D000505:Alopecia / Q000188:drug therapy / Q000276:immunology*; D000506:Alopecia Areata / Q000188:drug therapy / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000276:immunology
D001323:Autoantibodies; D007288:Inosine; D007542:Inosine Pranobex